EUVIMEDEUVIMED entdecken
Crossref

Ergothioneine Ameliorates Liver Fibrosis by Inhibiting Glycerophospholipids Metabolism and TGF‐β/Smads Signaling Pathway: Based on Metabonomics and Network Pharmacology

Yaping Mao, Zhenghui Xie, Xiangxia Zhang, Yu Fu, Xiaotong Yu, Lili Deng, Xiu Zhang, Bo Hou, Xiao Wang, Mingyue Ma iD, Fu Ren

Journal of Applied Toxicology · 2025

DOI: 10.1002/jat.4728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2025. Verfasst von Yaping Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology, School of Public Health, Shenyang Medical College, Shenyang, China. Hauptthemen laut MEDLINE: Signal Transduction, Ergothioneine, Transforming Growth Factor beta, Liver Cirrhosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Special Professor Project in Liaoning Province, Central Government Guides Local Science and Technology Development Fund, Society Service Station of Shenyang Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ergothioneine (EGT) is a diet‐derived natural sulfur‐containing amino acid that exhibits strong anti‐oxidant and anti‐inflammation activities. Oxidative stress and chronic inflammatory injury are predominant pro‐fibrogenic factors. Therefore, EGT may have therapeutic potential against liver fibrosis; however, its underlying mechanism is incompletely understood. This study aimed at investigating the protective effects of EGT on liver fibrosis based on metabonomics and network pharmacology. A mouse model of liver fibrosis was established by intraperitoneal injection with 40% CCl 4 solution (2 mL/kg, twice a week) and intragastric administration with EGT (5, 10 mg/kg/d) for six weeks. Results showed that EGT improved liver function by reducing serum levels of ALT (alanine aminotransferase), AST (aspartate aminotransferase), and TBIL (total bilirubin), and alleviated liver fibrosis by reducing LN (laminin) and HyP (hydroxyproline) levels, decreasing expressions of α‐SMA (α‐smooth muscle actin), Col‐I (collagen type I), and Col‐III (collagen type III), and improving pathological changes. EGT also significantly inhibited CCl 4 ‐induced hepatic inflammation and TGF‐β/Smads signaling pathway. Metabolomics identified six key metabolic pathways, such as purine metabolism, glycerophospholipid metabolism, and sphingolipid metabolism, and eight key metabolites, such as xanthine, guanine, ATP, phosphatidylcholine, and sphingosine. Network pharmacology analysis showed that IL‐17, cAMP and NF‐κB signaling pathways were potential key mechanisms. Integrated analysis revealed that PLA2G2A might be a potential target of EGT against liver fibrosis. EGT may inhibit the glycerophospholipid metabolism through PLA2G2A to inhibit the TGF‐β/Smads signaling pathway, thereby alleviating fibrosis. The present study indicates that EGT may be considered a valid therapeutic strategy to regress liver fibrosis, and provides novel insights into the pharmacological mechanism of EGT against liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionErgothioneineTransforming Growth Factor betaLiver CirrhosisGlycerophospholipidsSmad ProteinsAnimalsMetabolomicsNetwork PharmacologyMiceMaleLiverAntioxidantsCarbon Tetrachloride

Stichwörter der Autor:innen

TGF‐β/Smadsergothioneineinflammationliver fibrosismetabonomicsnetwork pharmacology

Substanzen

ErgothioneineTransforming Growth Factor betaGlycerophospholipidsSmad ProteinsAntioxidantsCarbon Tetrachloride

Autor:innen und Institutionen

  • Department of Toxicology, School of Public Health, Shenyang Medical College, Shenyang, China.
  • Department of Anatomy, School of Basic Medicine, Shenyang Medical College, Shenyang, China.
  • Department of Morphology, School of Nursing and Health, Qingdao Huanghai University, Qingdao, China.
  • Department of Gastroenterology, Central Hospital Affiliated to Shenyang Medical College, Shenyang, China.
  • Key Laboratory of Human Ethnic Specificity and Phenomics of Critical Illness in Liaoning Province, Shenyang Medical College, Shenyang, China.
  • Key Laboratory of Phenomics in Shenyang, Shenyang Medical College, Shenyang, China.

ORCID-Profile: Mingyue Ma

Förderung

  • Special Professor Project in Liaoning Province
  • Central Government Guides Local Science and Technology Development Fund
  • Society Service Station of Shenyang Medical College
  • Science and Technology Innovation Fund for Postgraduates of Shenyang Medical College

Zitieren

APA

Mao, Y., Xie, Z., Zhang, X., Fu, Y., Yu, X., Deng, L., Zhang, X., Hou, B., Wang, X., Ma, M., & Ren, F. (2025). Ergothioneine Ameliorates Liver Fibrosis by Inhibiting Glycerophospholipids Metabolism and TGF‐β/Smads Signaling Pathway: Based on Metabonomics and Network Pharmacology. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4728

Vancouver

Mao Y, Xie Z, Zhang X, Fu Y, Yu X, Deng L, et al. Ergothioneine Ameliorates Liver Fibrosis by Inhibiting Glycerophospholipids Metabolism and TGF‐β/Smads Signaling Pathway: Based on Metabonomics and Network Pharmacology. Journal of Applied Toxicology. 2025. doi:10.1002/jat.4728

BibTeX
@article{Mao2025,
  author = {Mao, Yaping and Xie, Zhenghui and Zhang, Xiangxia and Fu, Yu and Yu, Xiaotong and Deng, Lili and Zhang, Xiu and Hou, Bo and Wang, Xiao and Ma, Mingyue and Ren, Fu},
  title = {Ergothioneine Ameliorates Liver Fibrosis by Inhibiting Glycerophospholipids Metabolism and TGF‐β/Smads Signaling Pathway: Based on Metabonomics and Network Pharmacology},
  journal = {Journal of Applied Toxicology},
  year = {2025},
  doi = {10.1002/jat.4728}
}
Kostenlos starten →